Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

282309

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

The investigational therapy cavrotolimod (AST-008), in combination with the PD-1 inhibitor Keytruda (pembrolizumab), was safe and well-tolerated, and showed signs of efficacy in people with advanced solid tumors who failed prior PD-1 blockade therapy, according to the interim results of a Phase 1b/2 clinical trial. Based on these findings from the Phase 1b stage, the trial will continue in Phase 2 to investigate cavrotolimod plus Keytruda in people with advanced Merkel cell carcinoma (MCC), and…

You must be logged in to read/download the full post.